Yun Ho Bio Overview

  • Year Founded
  • 2022

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series C

  • Investors
  • 5

Yun Ho Bio General Information

Description

Developer of AI-assisted biopharmaceutical technologies designed for extrahepatic siRNA drug discovery and development. The company offers intelligent target identification, siRNA sequence optimization, predictive modeling, experimental design, data analysis, and therapeutic validation, thereby helping accelerate the development of safer and more effective treatments for extrahepatic diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 5, Innovation Center
  • Number 117 Zhujiang Road
  • Suzhou, Jiangsu 215000
  • China
+86 0512
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Vertical(s)
Big Data
Corporate Office
  • Building 5, Innovation Center
  • Number 117 Zhujiang Road
  • Suzhou, Jiangsu 215000
  • China
+86 0512

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Yun Ho Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 22-Sep-2026 Completed Generating Revenue
3. Early Stage VC 30-Mar-2026 Completed Generating Revenue
2. Early Stage VC (Series A) 05-Aug-2025 Completed Generating Revenue
1. Seed Round 25-Jul-2022 Completed Startup
To view Yun Ho Bio’s complete valuation and funding history, request access »

Yun Ho Bio Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 11

    Pending

  • Expiring in next 12 mo

Yun Ho Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026179919-A1 Double-target rnai agent and use thereof Pending 28-Feb-2025
WO-2026179917-A1 Rnai agent targeting angptl3 and pcsk9 and use thereof Pending 28-Feb-2025
WO-2026149467-A1 Rnai reagent for inhibiting ketohexokinase expression and use thereof Pending 09-Jan-2025
WO-2025162216-A1 Lipid oligonucleotide conjugate and use thereof Pending 30-Jan-2024
WO-2025153066-A1 Nucleic acid for inhibiting sodium voltage-gated channel alpha subunit 10 (scn10a) gene expression, and use thereof Pending 19-Jan-2024
To view Yun Ho Bio’s complete patent history, request access »

Yun Ho Bio Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Guanghua Kaiyuan Capital Asset Manager Minority
Xiaochi Capital Venture Capital Minority
Suzhou Oriza Holdings Corporation Asset Manager Minority
Ennovation Ventures Venture Capital Minority
Med-Fine Capital Venture Capital Minority
To view Yun Ho Bio’s complete investors history, request access »

Ready to get started?

Request a free trial

Yun Ho Bio FAQs

  • When was Yun Ho Bio founded?

    Yun Ho Bio was founded in 2022.

  • Where is Yun Ho Bio headquartered?

    Yun Ho Bio is headquartered in Suzhou, China.

  • What industry is Yun Ho Bio in?

    Yun Ho Bio’s primary industry is Discovery Tools (Healthcare).

  • Is Yun Ho Bio a private or public company?

    Yun Ho Bio is a Private company.

  • What is Yun Ho Bio’s current revenue?

    The current revenue for Yun Ho Bio is .

  • Who are Yun Ho Bio’s investors?

    Guanghua Kaiyuan Capital, Xiaochi Capital, Suzhou Oriza Holdings Corporation, Ennovation Ventures, and Med-Fine Capital have invested in Yun Ho Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process